Table S3.

Statistic analysis of the pharmacokinetic parameters

Group	P-value for t1/2	P-value for F0–t	P-value for Tmax
EDR suspension (172 µM/kg) vs NEF (46 µM/kg)	0.0252	<0.0001	0.9979
EDR suspension (172 µM/kg) vs NEF (138 µM/kg)	0.0005	<0.0001	0.9958
EDR suspension (172 µM/kg) vs NEF (414 µM/kg)	<0.0001	<0.0001	0.9914
NEF (46 µM/kg) vs NEF (138 µM/kg)	0.3147	0.0076	>0.9999
NEF (46 µM/kg) vs NEF (414 µM/kg)	0.0714	0.0448	0.9995
NEF (138 µM/kg) vs NEF (414 µM/kg)	0.8305	0.8460	>0.9999

Notes: t_1/2, half-life; T_max, peak time.

Abbreviations: EDR, edaravone; NEF, novel EDR formulation.